GlassScriptPhysician profile
Robert Paul Harris
NPI 1013914415
$1,086.05
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $223 · 2021: $136 · 2022: $74.22 · 2023: $92.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $92.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $92.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $286.28 | 2019-2023 | |
| Abbvie INC. | $186.30 | 2019-2021 | |
| Therapeuticsmd, INC. | $103.80 | 2019 | |
| Avion Pharmaceuticals | $92.73 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $72.49 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.70 | 2019-2020 | |
| Hologic Sales and Service, LLC | $45.26 | 2019-2020 | |
| Myriad Women'S Health, INC. | $44.56 | 2023 | Myrisk |
| Pfizer INC. | $33.39 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $28.92 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $27.99 | 2019-2020 | |
| Daiichi Sankyo INC. | $16.25 | 2020 | |
| Agile Therapeutics, INC. | $13.87 | 2021 | |
| Mission Pharmacal Company | $13.69 | 2020 | |
| Novo Nordisk INC | $12.90 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $12.82 | 2019 | |
| Exeltis, USA INC. | $12.71 | 2020 | |
| Sage Therapeutics, LLC | $12.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.